The DOI matches its Crossref record.
The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15
Open accessAbstract
Steroid compounds, which are expected to have dual functions in blocking host inflammation and MERS-CoV replication, were screened from a chemical library. Within this library, ciclesonide, an inhaled corticosteroid, suppressed human coronavirus replication in cultured cells, but did not suppress replication of respiratory syncytial virus or influenza virus. The effective concentration of ciclesonide to block SARS-CoV-2 (the cause of COVID-19) replication (EC 90 ) was 6.3 μM. After the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, which resulted in an amino acid substitution (A25V) in nonstructural protein (NSP) 15, as identified using reverse genetics. A recombinant virus with the mutation was also resistant to ciclesonide suppression of viral replication. These observations suggest that the effect of ciclesonide was specific to coronavirus, suggesting this is a candidate drug for treatment of patients suffering MERS or COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 11
- 2020, Drug treatment options for the 2019-new coronavirus (2019-nCoV), Biosci. Trends A, 01020, 10
- M. Wang , et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2019–2021 (2020). · DOI · Paper page
- 2019, Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection□: A cohort study, 29, 48
- 10.1016/j.jcv.2004.07.006 · DOI · Paper page
- 10.3391/mbi.2017.8.1.01 · DOI · Paper page
- 10.1073/pnas.1618310114 · DOI · Paper page
- A. Lundin , et al., Targeting Membrane-Bound Viral RNA Synthesis Reveals Potent Inhibition of Diverse Coronaviruses Including the Middle East Respiratory Syndrome Virus. PLoS Pathog. 10(2014). · DOI
- 2017, MERS coronavirus nsp1 participates in an efficient propagation through a specific interaction with viral RNA, Virology, 511, 95, 10.1016/j.virol.2017.08.026 · DOI
- 2020, Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Euro Surveill., 25, 1
- 2018, Structural and Biochemical Characterization of Endoribonuclease Nsp15 Encoded by Middle East Respiratory Syndrome Coronavirus, J. Virol., 92, 1
- 10.1128/JVI.01890-13 · DOI · Paper page
Cited by
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
Jeon, S., Ko, M., Lee, J., Choi, I., Byun, S. Y., Park, S., Shum, D., & Kim, S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00819-20 · Cited by 675
Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?
Halpin, D. M. G., Faner, R., Sibila, O., Badia, J. R., & Agusti, A. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30167-3 · Cited by 385
Structural insights into SARS-CoV-2 proteins
Arya, R., Kumari, S., Pandey, B., Mistry, H., Bihani, S. C., Das, A., Prashar, V., Gupta, G. D., Panicker, L., & Kumar, M. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.11.024 · Cited by 348
Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective
Halpin, D. M. G., Singh, D., & Hadfield, R. M. (2020) · European Respiratory Journal · doi:10.1183/13993003.01009-2020 · Cited by 310
Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19
Chhiba, K. D., Patel, G. B., Vu, T. H. T., Chen, M. M., Guo, A., Kudlaty, E., Mai, Q., Yeh, C., Muhammad, L. N., Harris, K. E., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.06.010 · Cited by 308
Metadata
- Authors
- Matsuyama, S., Kawase, M., Nao, N., Shirato, K., Ujike, M., Kamitani, W., Shimojima, M., & Fukushi, S.
- Venue
- bioRxiv (Cold Spring Harbor Laboratory)
- Publisher
- openRxiv
- Published
- 2020-03-12
- OpenAlex
- W3012236996
- Cited by
- 179
- References
- 0
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. https://app.cochat.ai/papers/10.1101/2020.03.11.987016
- The paper
- Matsuyama, S., Kawase, M., Nao, N., Shirato, K., Ujike, M., Kamitani, W., Shimojima, M., & Fukushi, S. (2020). The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2020.03.11.987016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.